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The problem of antibiotic resistance, which has limited the use of cheap and old antibiotics, has 
necessitated the need for a continued search for new antimicrobial compounds. Understanding the 
mechanisms of resistance is important in the development of strategies to solving the problem. Active 
efflux of drugs, alteration of target sites and enzymatic degradations are the strategies by which 
pathogenic bacteria acquire or develop intrinsic resistance to antibiotics. Multi-drug resistance (MDR) 
pumps, capable of recognizing and expelling a variety of structurally unrelated compounds from the 
bacterial cell and conferring resistance to a wide range of antibiotics have since been characterized in 
many gram positive and gram negative pathogens like Staphylococcus aureus, Pseudomonas 
aeruginosa, Escherichia coli and, more recently, in mycobacteria. The ability of some chemical 
compounds (called MDR inhibitors or resistance modifying agents) to modify the resistance phenotype 
in bacteria by working synergistically with antibiotics in vitro has since been observed. The search for 
such compounds which can be combined with antibiotics in the treatment of drug resistant infections 
may be an alternative to overcoming the problem of resistance in bacteria. Crude extracts of medicinal 
plants stand out as veritable sources of potential resistance modifying agents and the African 
biosphere promises to be a potential source of such compounds owing to its rich plant species 
diversity.  
 





Since the discovery of antibiotics and their uses as che-
motherapeutic agents, there was a belief in the medical 
fraternity that this would lead to the eradication of infec-
tious diseases. However diseases and disease agents 
that were once thought to have been controlled by 
antibiotics are returning in new forms resistant to antibio-
tic therapies (Levy and Marshall, 2004). Incidents of 
epidemics due to such drug resistant microorganisms are 
now a common global problem posing enormous public 
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of multi-drug resistant bacterial strains is increasingly 
limiting the effectiveness of current drugs and significant-
ly causing treatment failure of infections (Hancock, 2005). 
Examples include methicillin-resistant staphylococci, 
pneumococci resistant to penicillin and macrolides, 
vancomycin-resistant enterococci as well as multidrug-
resistant gram-negative organisms (Norrby et al., 2005).  
As resistance to old antibiotics spreads, the develop-
ment of new antimicrobial agents has to be expedited if 
the problem is to be contained. However, the past record 
of rapid, widespread and emergence of resistance to 
newly introduced antimicrobial agents indicates that even 
new families of antimicrobial agents will have a short life 






Confronted with a possible shortage of new antimi-
crobials, there is need to ensure a careful use of our 
available drugs. This has led to calls for controlled use of 
antibiotics through the reduction of dosage used per 
regime of treatment or by regulating prescriptions in 
areas such as animal husbandry and aquaculture 
(Hernandez, 2005). While reduced use could lead to 
delayed resistance development, the emergence of 
resistant strains is from an evolutionary viewpoint inevita-
ble. It becomes imperative therefore that alternative 
approaches are explored. Targeting and blocking resis-
tance processes could be an attractive approach. The 
presence of efflux pumps and multidrug resistance 
(MDR) proteins in antibiotic resistant organisms contri-
bute significantly to the intrinsic and acquired resistance 
in these pathogens. The discovery and development of 
new compounds that either block or circumvent 
resistance mechanisms could improve the containment, 
treatment, and eradication of these strains (Oluwatuyi et 
al., 2004). A few studies such as Gibbons et al. (2003), 
Dickson et al. (2006) and Braga et al. (2005) have 
reported that plant extracts can enhance the in vitro 
activity of certain antibiotics against strains of MDR 
Staphylococcus aureus and other pathogens. These 
studies have prompted the search for such MDR Pump or 
Efflux Pump inhibitors from medicinal plants. This paper 
reviews the mechanisms of resistance to antibiotics by 
pathogenic bacteria and how such processes can be 
curtailed by the use of plant extracts and plant derived 
compounds in a bid to highlighting the importance of this 
untapped resource in the fight against the spread of 
antibiotic resistant pathogens.     
 
 
THE CHALLENGE OF ANTIBIOTIC RESISTANCE 
 
The development of resistance in bacteria is one of the 
mechanisms of natural adaptation to the presence of an 
antimicrobial agent that inhibits susceptible organisms 
and selects the resistant ones. Under continued selection 
pressure, the selected resistant organisms multiply and 
spread to other geographic locations as well as to other 
microbes by transfer of resistance genes (Levy and 
Marshall, 2004). Selection of resistant strains occurs so 
rapid for some bacteria that clinical usefulness of the 
antibiotics is lost within a 5 year period (Bush, 2004).  
The emergence and spread of microbes that are 
resistant to cheap and effective first-choice drugs has 
become a common occurrence. The problem is even 
more evident in bacterial infections which contribute most 
to the global infectious disease burden such as diarrheal, 
respiratory tract, meningitis, sexually transmitted infec-
tions, and tuberculosis (WHO, 2002). Resistance to 
penicillin in S. aureus first appeared in 1942 immediately 
following its clinical use. By the late 1960s, more than 
80% of both community- and hospital-acquired staphylo-
coccal isolates were resistant  to  penicillin  (Lowy,  2003).  




At present most clinical isolates of S. aureus are multiple-
drug resistant (resistant to three or more of agents such 
as ciprofloxacin, erythromycin, clindamycin, gentamicin, 
trimethoprim/sulphamethoxazole, linezolid, and vancomy-
cin) (Styers et al., 2006). Global resistance rates in S. 
pyogenes isolates are as high as 80% for erythromycin 
and 50% for penicillins (Low, 2005). Recently, strains of 
Mycobacterium tuberculosis that are resistant to virtually 
all classes of drugs currently available for the treatment 
of TB (isoniazid, rifampicin, fluoroquinolones, aminogly-
cosides (amikacin, kanamycin and capreomycin) have 
been identified in the KwaZulu Natal Province of South 
Africa (Gandhi et al., 2006) earning a new classification 
termed, Extremely Drug Resistant Tuberculosis (XDR 
TB).  
When infections become resistant to first choice or first-
line antimicrobials, treatment has to be switched to 
second- or third-line drugs, which are nearly always 
expensive. In many poor countries, the high cost of such 
replacement drugs is prohibitive, with the result that some 
diseases can no longer be treated in areas where 
resistance to first-line drugs is widespread (WHO, 2002). 
Faced with such a challenge, there is need to develop 
alternative approaches in addition to the search for new 
antimicrobial compounds. Such approaches might 
include strategies that target resistance mechanisms 
coupled with antibiotics.   
 
 
MECHANISMS OF ANTIBIOTIC RESISTANCE IN 
PATHOGENIC BACTERIA 
 
Resistance to antimicrobials is as a result of three main 
strategies namely enzymatic inactivation of the drug 
(Davies, 1994), modification of target sites (Spratt, 1994) 
and extrusion by efflux (Nakaido, 1994). While chemical 
modifications could be significant in antibiotic resistance, 
exclusion from the cell of unaltered antibiotic represents 
the primary strategy in denying the antibiotic, access to 
its targets and this is believed to enhance resistance 
even in cases where modification is the main mechanism 
(Li et al., 1994b).   
 
 
Alteration of target site  
 
Chemical modifications in the antibiotic target may result 
in reduced affinity of the antibiotic to its binding site 
(Lambert, 2005). This is a mechanism employed by a 
number of pathogenic bacteria in evading the effect of 
antibiotics. Modifications are usually mediated by consti-
tutive and inducible enzymes. Resistance to macrolides, 
lincosamide and streptogramin B antibiotics (MLSB 
resistance) in pathogenic Streptococcus species is a 
result of methylation of the N6 amino group of an adenine 
residue in 23S rRNA. This is presumed to cause confor-
mational changes  in  the  ribosome  leading  to  reduced  
 




binding affinity of these antibiotics to their binding sites in 
the 50S ribosomal subunit (Seppala et al., 1998; Kataja 
et al., 1998). Beta-lactams antibiotics function by binding 
to and inhibiting the biosynthetic activity of Penicillin 
Binding Proteins (PBPs), thereby blocking cellwall 
synthesis. In S. aureus and S. pneumoniae, resistance to 
-lactams can be a result of mutations leading to the 
production of PBP2a and PBP2b respectively. The two 
proteins have a reduced affinity for -lactams and yet 
they take over the functions of normal PBPs in the 
presence of inhibitory levels of -lactams (Golemi-Kotra 
et al., 2003; Grebe and Hakenbeck, 1996). This 
mechanism of resistance is also responsible for -lactam 
resistance in non- - lactamase producing Haemophillus 
influenza (Matic et al., 2003).  
 
 
Enzymatic inactivation  
 
The production of hydrolytic enzymes and group 
transferases is a strategy employed by a number of 
pathogens in evading the effect of antibiotics (Wright, 
2005). Genes that code for antibiotic degrading enzymes 
are often carried on plasmids and other mobile genetic 
elements. The resistance to -lactam antibiotics by both 
gram negative and gram positive bacteria has long been 
attributed to -lactamases (Frere, 1995). These enzymes 
confer significant antibiotic resistance to their bacterial 
hosts by hydrolysis of the amide bond of the four-
membered -lactam ring (Wilke et al., 2005). Resistance 
to aminoglycosides in gram-negative bacteria is most 
often mediated by a variety of enzymes that modify the 
antibiotic molecule by acetylation, adenylation or 
phosphorylation (Over et al., 2001). 
 
 
Antibiotic efflux  
 
It is now widely recognized that constitutive expression of 
efflux pump proteins encoded by house-keeping genes 
that are widespread in bacterial genomes are largely 
responsible for the phenomenon of intrinsic antibiotic 
resistance (Lomovskaya and Bostian, 2006). Several 
studies have shown that active efflux can be a 
mechanism of resistance for almost all antibiotics (Li et 
al., 1994a; Gill et al., 1999; Lin et al., 2002). The majority 
of the efflux systems in bacteria are non-drug-specific 
proteins that can recognize and pump out a broad range 
of chemically and structurally unrelated compounds from 
bacteria in an energy-dependent manner, without drug 
alteration or degradation (Kumar and Schweizer, 2005). 
The consequence of this drug extrusion is that, it leads to 
a reduced intracellular concentration of the antimicrobial 
such that the bacterium can survive under conditions of 
elevated antimicrobial concentration (Marquez, 2005). 
The MIC of the drug against such organisms will be 





Multi-drug resistance efflux pumps are ubiquitous 
proteins present in both gram-positive and gram-negative 
bacteria as either chromosomally encoded or plasmid 
encoded (Akama et al., 2005). Although, such proteins 
are present constitutively in bacteria, the continued 
presence of the substrate induces over-expression 
(Teran et al., 2003). This increased transcription is 
responsible for the acquired resistance. In gram-
negatives bacteria, the effect of the efflux pumps in 
combination with the reduced drug uptake due to the 
double membrane barrier is responsible for the high 
inherent and acquired antibiotic resistance often associa-
ted with this group of organisms (Lomovskaya and 
Bostian, 2006).  
Efflux transporters constitute about 6 to 18% of all 
transporters found in any given bacterial cell (Paulsen et 
al., 1998). Currently, much attention is being paid to-
wards understanding the operating mechanisms of these 
pumps. This has potential applications in the design of 
transport inhibitors that could be used in combination with 
antibiotics in development of clinically useful drugs 
(McKeegan et al., 2004). 
The MDR pumps of pathogenic bacteria known so far, 
belong to five families of transporters namely; the major 
facilitator super-family (MFS), the adenosine triphosphate 
(ATP)-binding cassette (ABC) super-family, the small 
multi-drug resistance (SMR) family and the resistance-
nodulation-cell division (RND) super-family and the multi-
drug and toxic compound extrusion (MATE) family 
(Kumar and Schweizer, 2005).  
 
 
Some characterized efflux proteins of pathogenic 
bacteria 
 
The NorA protein of S. aureus is the best studied 
chromosomally encoded pump in pathogenic gram-
positive bacteria (Hooper, 2005). It is present in S. 
epidermidis but appears to be absent in Enterococcus 
faecalis or in gram-negative organisms, such as E. coli 
and K. pneumoniae (Kaatz et al., 1993). Overexpression 
of the NorA gene in S. aureus confers resistance to 
chloramphenicol and hydrophilic fluoroquinolone antimi-
crobials (Hooper, 2005; Kaatz and Seo, 1995).  
QacA is a member of the major facilitator super-family 
of transport proteins, which are involved in the uniport, 
symport, and antiport of a wide range of substances 
across the cell membrane (Mitchell et al., 1998). The 
QacA multidrug exporter from S. aureus mediates resis-
tance to a wide array of monovalent or divalent cationic, 
lipophilic, antimicrobial compounds. QacA provides resis-
tance to these various compounds via a proton motive 
force-dependent antiport mechanism (Brown and 
Skurray, 2001). 
The mefA efflux protein of S. pyogenes is a 
hydrophobic 44.2 kDa transposon encoded protein, of the 






crolides (Kohler et al., 1999) resulting in the M phenotype 
in S. pyogenes (Sutcliffe et al., 1996). It shares a 90% 
amino acid homology with MefE (Roberts et al., 1999) of 
S. pneumoniae that also mediates the efflux of macro-
lides.  
PmrA (pneumococcal multidrug resistance protein) 
efflux of S. pneumoniae is a chromosomally encoded 
protein of the Major facilitator family that confers a 
resistance profile in S. pneumonia similar to that of NorA 
in S. aureus (Kohler et al., 1999). The efflux protein which 
is not expressed constitutively in pneumococcal strains is 
responsible for low-level fluoroquinolone resistance in 
pneumococci (Kohler et al., 1999; Gill et al., 1999). 
AcrAB-TolC pump is a member of the Resistance-
Nodulation-cell division (RND) family of tripartite multi-
drug efflux pumps ubiquitous throughout gram-negative 
bacteria. In Escherichia coli, the multidrug efflux pump 
has been shown to expel a wide range of antibacterial 
agents (Touze et al., 2004). The resistance to 
fluororoquinolones, chloramphenicol-florfenicol and tetra-
cycline in the food borne pathogen Salmonella enterica 
serovar Typhimurium definitive phage type 104 is highly 
dependent on the presence of AcrAB-TolC efflux pump 
(Baucheron et al., 2004). The tripartite pump is also the 
major efflux mechanism of the nosocomial pathogen 
Enterobacter aerogenes (Masi et al., 2003; Pradel and 
Pages, 2002). The pump has also been associated with 
baseline level resistance of H. influenzae Rd to 
erythromycin, rifampin, novobiocin, and dyes such as 
ethidium bromide and crystal violet (Sanchez et al., 
1997). 
The RND family efflux pump, MexAB-OprM, of the 
opportunistic pathogen, Ps. aeruginosa has been 
extensively characterized. Like other tripartite efflux 
proteins, it consists of three membrane bound subunits, 
MexA, MexB, and OprM, anchoring the inner and outer 
membranes. The MexB subunit is central to the pump 
function, which spans the cytoplasmic membrane 12 
times, it selects antibiotics to be exported, and is 
assumed to transport the substrates expending the 
energy of the proton gradient across the cytoplasmic 
membrane (Akama et al., 2004). Resistance to –lactams 
and non--lactam antibiotics such as quinolones, 
tetracyclines, and trimethoprim has been attributed to 
efflux by the MexAB-OprM pump (Ziha-Zarifi et al., 1999). 
Other Mex efflux proteins namely mexCD, mexEF MexXY 
mediating multidrug resistance have also been cloned 




THE USE OF RESISTANCE MODIFYING AGENTS IN 
COMBINATION WITH ANTIBIOTICS TO OVERCOME 
RESISTANCE 
 
The selection pressure exerted by the continued 
presence of  bactericidal  or  bacteriostatic  agents  facili- 




tates the emergence and dissemination of antibiotic 
resistance genes. Over generations, the genotypic 
makeup of bacterial populations is altered (Taylor et al., 
2002). The clinical implications of this are that many 
infections become untreatable resulting in serious 
morbidity and mortality. Although the introduction of new 
compounds into clinical use has helped to curtail the 
spread of resistant pathogens, resistance to such new 
drugs, has developed in some cases. For instance, 
resistance to the lipopeptide, daptomycin among clinical 
isolates of Enterococcus faecium has already been 
detected (Pankey et al., 2005). This is despite the fact 
that the drug was first licensed in 2003 (Norrby et al., 
2005).  
It has been observed by several studies that antibiotic 
combinations can have synergistic benefits and 
interactions between existing antibiotics (Bayer et al., 
1980; Hooton et al., 1984; Cottagnoud et al., 2000; 
Hallander et al., 1982). Several current therapeutic 
regimes are based on synergistic interactions between 
antibiotics with different target sites. As new antimicrobial 
compounds are discovered, there is need to assess their 
potentials in combination therapies with old antibiotics 
that have been rendered ineffective by the development 
of resistant strains, even when such compounds are not 
directly evidently inhibitory. Taylor et al., (2002) 
suggested that the use of agents that do not kill 
pathogenic bacteria but modify them to produce a 
phenotype that is susceptible to the antibiotic could be an 
alternative approach to the treatment of infectious 
disease. Such agents could render the pathogen 
susceptible to a previously ineffective antibiotic, and 
because the modifying agent applies little or no direct 
selective pressure, this concept could slow down or 
prevent the emergence of resistant genotypes. The 
inhibition of resistance expression approach was 
successfully used in the production of Augmentin, a 
combination of amoxycillin and clavulanic acid (Reading 
and Cole, 1977). In this case, clavulanic acid is an 
inhibitor of class-A -lactamases which is co-
administered with amoxicillin. The combination has been 
used clinically since the late 1970s (Neu et al., 1993). A 
similar approach can be used for target-modifying 
enzymes and for efflux systems.  
A number of in vitro studies have reported the use of 
plant extracts in combination with antibiotics, with 
significant reduction in the MICs of the antibiotics against 
some resistant strains (Al-hebshi et al., 2006; Darwish et 
al., 2002; Betoni et al., 2006). The curative effect of plant 
extracts in this combination study has been variably 
referred to as resistance modifying/modulating activity 
(Gibbons, 2004). This ability of plant extracts to 
potentiate antibiotics has not been well explained. It is 
speculated that inhibition of drug efflux, and alternative 
mechanisms of action could be responsible for the 
synergistic interactions between plant extracts and 
antibiotics (Lewis and Ausubel, 2006; Zhao et al., 2001).  
 




Efflux pump inhibition in combination with antibiotics 
as a strategy for overcoming resistance  
 
The discovery and development of clinically useful Efflux 
Pump Inhibitors (EPIs) that decrease the effectiveness of 
efflux pumps represents a significant advance in the 
development of therapeutic regimes for the treatment of 
MDR-related conditions. This approach termed the EPI 
strategy (Lomovskaya and Bostian, 2006), is based on 
blocking the activity of the pumps, resulting in the 
accumulation of the antibiotic inside the bacterial cell, 
consequently increasing access to its target sites. In 
addition, this will lead to increased susceptibility of the 
bacterium, thus implying that the therapeutic effect of the 
drug is achieved with low concentrations. Combining 
broad spectrum efflux pump inhibitors with current drugs 
that are pump substrates can recover clinically relevant 
activity of those compounds and thus may provide new 
dimensions to the ever increasing need for development 
of new antimicrobial agents (Kaatz, 2002). This approach 
will in addition lead to the preservation and improvement 
of the usefulness of old and cheap antibacterial agents. 
Ultimately this could reduce the appearance and spread 
of resistant mutants (Kaatz, 2002). 
 
 
Multiple targets and mutual interference strategies  
 
A combination of antimicrobials with different target sites 
and mechanisms of action can be beneficial in reducing 
resistance development. The likelihood that a pathogen 
could simultaneously develop resistance against more 
than one drug is low (Dryselius et al., 2005). Other 
combinations may involve antibiotics and other com-
pounds that are not antimicrobial but can enhance the 
activity of the antibiotics. Combinations between antibio-
tics and known or new antimicrobial compounds might 
uncover some beneficial potential that might be useful in 
curbing resistance to antibiotics.     
Some drug formulations in current use are already 
based on the concept of dual targets or mutual interfe-
rence (Rossolini and Mantengoli, 2005). For instance, the 
combination of trimethoprim and sulphamethoxazole, (co-
trimoxazole) involves a mutual interference of two 
sequential steps in the bacterial folate biosynthesis 
pathway. Sulphamethoxazole competitively inhibits 
bacterial dihydropteroate synthetase, an enzyme involved 
in the first step in the reaction leading to folic acid 
synthesis. Trimethoprim, inhibits the enzyme dihydrofo-
late reductase, involved in the next step in the folic acid 
pathway (Jerry and Smilack, 1999). Beta-lactamase 
inhibitors, clavulanic acid and sulbactam have been used 
to enhance the activity of beta lactam antibiotics against 
beta lactamase producing organisms (Moosdeen et al., 
1988; Maddux, 1991).  
The synergy between epigallocatechin gallate (EGCg) 





antimicrobial activity of tea) and oxacillin observed by 
Zhao et al. (2001) was attributed to the combined action 
of EGCg and Oxacillin on the biosynthesis of the cell wall 
thereby bypassing the resistance mechanism resulting 
from the reduced affinity of Penicillin Binding Proteins 
(PBP) to Oxacillin.  
 
 
PLANTS AS SOURCES OF NEW ANTIMICROBIALS 
AND RESISTANCE MODIFYING AGENTS 
 
Plants have traditionally provided a source of hope for 
novel drug compounds, as plant herbal mixtures have 
made large contributions to human health and well-being 
(Iwu et al., 1999). Owing to their popular use as remedies 
for many infectious diseases, searches for substances 
with antimicrobial activity in plants are frequent (Betoni et 
al., 2006; Shibata et al., 2005). Plants are rich in a wide 
variety of secondary metabolites, such as tannins, 
terpenoids, alkaloids, and flavonoids, which have been 
found in vitro to have antimicrobial properties (Lewis and 
Ausubel, 2006; Cowan, 1999). Examples of some of 
these compounds are shown in Table 1. Literature is 
awash with compounds that have been isolated from a 
variety of medicinal plants. Despite this abundant 
literature on the antimicrobial properties of plant extracts, 
none of the plant derived chemicals have successfully 
been exploited for clinical use as antibiotics (Gibbons, 
2004). 
A significant part of the chemical diversity produced by 
plants is thought to protect plants against microbial 
pathogens. Gibbons (2004), observes that a number of 
plant compounds often classified as antimicrobial 
produce MIC ranges greater than 1,000 µg/ml which are 
of no relevance from a clinical perspective. Tegos et al. 
(2002) suggests that a vast majority of plant compounds 
showing little in vitro antibacterial activity are not 
antimicrobial but are regulatory compounds playing an 
indirect role in the plant defence against microbial 
infections.  
The observation that plant derived compounds are 
generally weak compared to bacterial or fungal produced 
antibiotics and that these compounds often show 
considerable activity against gram-positive bacteria than 
gram-negative species has been made by many (Nostro 
et al., 2000; Gibbons, 2004). This led to Tegos et al. 
(2002) hypothesizing that; Plants produce compounds 
that can be effective antimicrobials if they find their way 
into the cell of the pathogen especially across the double 
membrane barrier of Gram negative bacteria. Production 
of efflux pump inhibitors by the plant would be one way to 
ensure delivery of the antimicrobial compound. This 
hypothesis has been supported by the findings of 
Stermitz et al. (2000 a,b), who observed that Berberis 
plants which produce the antimicrobial compound, 
berberine, also make the MDR inhibitors 5-methoxyhyd-
nocarpin D (5-MHC-D)  and  pheophorbide  A.  The  MDR  
 




Table 1. Examples of some plant derived compounds with antimicrobial value. 
 
Class of compound Examples Plant sources Reference 




























Bylka et al. (2004) 
 
Takahashi et al. (2004) 
 






Tshikalange et al. (2005) 
 
Madubunyi (1995)  































Smith et al. (2007) 
 
 




inhibitors facilitated the penetration of berberine into a 
model gram-positive bacterium, S. aureus. In testing their 
hypothesis, Tegos et al. (2002), showed that two MDR 
inhibitors (INF271 and MC207110) dramatically increased the 
effectiveness of thirteen putative plant antimicrobial 
compounds against gram-negative and gram positive 
bacteria including isolates known to express efflux 
pumps.  
These studies have provided the bases for 
understanding the action of plant antimicrobials, namely 
that vast majority of such compounds are agents with 
weak or narrow-spectrum activities that act in synergy 
with intrinsically produced efflux pump inhibitors. There is 
reason therefore to believe that, plants could be a source 
of compounds that can increase the sensitivity of 
bacterial cells to antibiotics. Such compounds could be 
useful particularly against antibiotic resistant strains of 
pathogenic bacteria. The rich chemical diversity in plants 
promises to be a potential source of antibiotic resistance 
modifying compounds and has yet to be adequately 
explored.    
Resistance modifying activities of plants crude 
extracts: the basis for isolation of potentially useful 
compounds 
 
If the isolation of resistance modifying compounds from 
plants is to be realistic, screening for such activities in 
crude extracts is the first step in identifying leads for 
isolation of such compounds, and some plants have 
provided good indications of these potentials for use in 
combination with antimicrobial therapy. Typical examples 
are as follows: 
 
Aqueous extracts of tea (Camellia sinensis) have been 
shown to reverse methicillin resistance in MRSA and 
also, to some extent, penicillin resistance in beta-
lactamase-producing Staphylococcus aureus (Stapleton 
et al., 2004).  Forty to one hundred fold dilutions of tea 
extracts was able to reduce the MICs of high- level 
resistant MRSA ( 256 µg/ml) to less than 0.12 µg/ml for 
methicillin and penicillin (Yam et al., 1998; Stapleton et 
al., 2004). Aqueous crude khat (Catha edulis) extracts  of  
 




Yemen showed varying antibacterial activities with a 
range of 5-20 mg/ml-1 against periodontal bacteria when 
tested in isolation. Addition of the extracts at a sub- MIC 
(5 mg/ml) resulted in a 2 to 4-folds potentiation of 
tetracycline against resistant strains Streptococcus 
sanguis TH-13, Streptococcus oralis SH-2, and 
Fusobacterium nucleatum (Al-hebshi et al., 2006). Betoni 
et al. (2006), observed synergistic interactions between 
extracts of guaco (Mikania glomerata), guava (Psidium 
guajava), clove (Syzygium aromaticum), garlic (Allium 
sativum), lemongrass (Cymbopogon citratus), ginger 
(Zingiber officinale), carqueja (Baccharis trimera), and 
mint (Mentha Pieria) from Brazil  and some antibiotics 
which represented inhibitors of protein synthesis, cell wall 
synthesis, nucleic acid synthesis and folic acid synthesis 
against Staphylococcus aureus. Darwish et al., (2002) 
reported that sub-inhibitory levels (200 µgml−1) of metha-
nolic extracts of some Jordanian plants showed synergis-
tic interactions in combination with chloramphenicol, 
gentamicin, erythromycin and penicillin G against 
resistant and sensitive S. aureus. The methanolic extract 
of Punica granatum (PGME) showed synergistic interac-
tions with chloramphenicol, gentamicin, ampicillin, 
tetracycline, and oxacillin. The bactericidal activity of the 
combination of PGME (0.1×MIC) with ampicillin 
(0.5×MIC) by time-kill assays, reduced cell viability by 
99.9 and 72.5% in MSSA and MRSA populations, 
respectively (Braga et al., 2005). The ethanol extracts of 
the Chinese plants, Isatis tinctoria and Scutellaria 
baicalensis in combination with ciprofloxacin had 
synergistic activities against antibiotic resistant S. aureus 
(Yang et al., 2005). The combinations of pencillin with 
ethanolic extracts of Paederia scandens and Taraxacun 
monlicum showed a strong bactericidal activity on two 
strains of S. aureus (Yang et al., 2005). When 
Ciprofloxacin was incorporated at sub-inhibitory 
concentrations (1/8MIC) to the crude chloroform extracts 
of Jatropha elliptica and the mixture assayed against 
NorA expressing S. aureus, the activity of the extract was 
enhanced. This suggests the presence of an inhibitor of 
the pump which could restore the activity of Ciprofloxacin 
(Marquez et al., 2005). In another study, Ahmad and Aqil, 
(2006) observed that crude extracts of Indian medicinal 
plants, Acorus calamus, Hemidesmus indicus, 
Holarrhena antidysenterica and Plumbago zeylanica 
showed synergistic interactions with tetracycline and 
ciprofloxacin against Extended Spectrum -lactamase 
(ESL), producing multidrug-resistant enteric bacteria 




Plant compounds with resistance modifying activities 
 
Some isolated pure compounds of plant origin have been 
reported to have resistance modifying activities in vitro. 
Examples of some of the compounds are given in Table 





from a variety of medicinal plants. Some of the com-
pounds which have been observed to have direct 
antimicrobial activity have also been shown to be 
potentiate against the activity of antibiotics when used at 
low MIC levels. 
The antimicrobial properties of tea (Camellia sinensis) 
have been found to be a result of the presence of 
polyphenols (Yam et al., 1998; Stapleton et al., 2004; Si 
et al., 2006). Bioassay directed fractionation of the 
extracts revealed that epicatechin gallate (ECG), 
epigallocatechin gallate (EGCG), epicatechin (EC), and 
caffeine (CN) are the bioactive components. ECG and 
CG reduced MIC values for oxacillin from 256 and 512 to 
1 and 4 mgl-1 against MRSA (Shibata et al., 2005). Ethyl 
gallate, a conginer of alkyl gallates purified from a dried 
pod of tara (Caesalpinia spinosa) native to South 
America, intensified -lactam susceptibility in MRSA and 
MSSA strains (Shibata et al., 2005). The abietane 
diterpenes, (carnosic acid carnosol) isolated from the 
aerial parts of Rosmarinus officinalis by fractionation of 
the chloroform extract at 10 µgml-1, potentiated the 
activity of erythromycin (16 - 32 fold) against strains of S. 
aureus that express the two efflux proteins MsrA and 
TetK. Additionally, carnosic acid was shown to inhibit 
ethidium bromide efflux in a NorA expressing S. aureus 
strain (Oluwatuyi et al., 2004). A penta-substituted 
pyridine, 2, 6-dimethyl-4-phenylpyridine-3, 5-dicarboxylic 
acid diethyl ester and proparcine have been isolated from 
an ethanol extract of rhizome of Jatropha elliptica by 
bioassay guided fractionation. The pyridine at a concen-
tration of 75 µgml-1 was shown to increase by 4-fold, the 
activity of ciprofloxacin and norfloxacin against NorA 
expressing S. aureus when tested at sub-inhibitory 
concentrations (Marquez et al., 2005). Smith et al. (2007) 
screened active compounds from the cones of 
Chamaecyparis Lawsoniana for resistance modifying 
activities and observed that Ferruginol and 5-Epipisiferol 
were effective in increasing the efficacy of tetracycline, 
norfloxacin, erythromycin and Oxacillin against resistant 
S. aureus. The majority of researches on the combina-
tions between plant extracts and antibiotics have been 
focused on the identification and isolation of potential 
resistance modifiers from such natural sources which are 
considered to be positive results. However, it is likely that 
such combinations could produce antagonistic interac-
tions that most studies have considered irrelevant and 





While there is an abundance of published data validating 
the antimicrobial activity of medicinal plants commonly 
used in folk medicine, this has not resulted in the 
identification of commercially exploitable plant derived 
antibacterial agents (Lewis and Ausubel, 2006). The ma-
jority of plant derived antimicrobial  compounds  generally  
 




Table 2. Some antibiotic resistance modifying compounds from plants.  
 










Smith et al. (2007) 
2,6-dimethyl-4-phenyl- 
pyridine-3,5-dicarboxylic 
acid diethyl ester 
Jatropha elliptica Ciprofloxacin, Norfloxacin,  
Pefloxacin, Acriflavine and  
Ethidium bromide 
 
Marquez et al. (2005) 
Carnosic acid carnosol Rosmarinus officinalis Erythromycin Oluwatuyi et al. (2004) 
 










Lycopus europaeus Tetracycline and  
Erythromycin 
Gibbons et al. (2003) 
Epicatechin gallate  
 
Epigallocatechin gallate 




Gibbons et al. (2004) 
Hu et al. (2002) 




have higher MICs than bacterial or fungal produced 
antibiotics, thus limiting their therapeutic potential 
(Gibbons, 2004). The findings of Tegos et al. (2002) have 
provided a foundation for a rationale on the potential 
actions of plant derived antimicrobial compounds and 
other compounds with no intrinsic antimicrobial value. It 
has already been established that crude extracts of some 
medicinal plants and some pure compounds from such 
plants can potentiate the activity of antibiotics in vitro 
(Marquez et al., 2005; Smith et al., 2007). This search for 
antibiotic resistance modulators in plants represents a 
new dimension to addressing the problem of antibiotic 
resistance. The chemical diversity available in plants still 
remains largely uninvestigated for potentials in improving 
the clinical efficacy of antibiotics. Most interestingly are 
medicinal plants and food plants which are inadvertently 
used with antibiotics in common community practices 
providing opportunities for interactions. As many medi-
cinal plants still remain unexplored, there are enormous 
opportunities for the discovery of novel resistance modi-
fying compounds of plant origins. Screening of antibiotic 
resistance modifying compounds from plants sources are 
expected to provide the basis for identifying leads for the 
isolation of therapeutically useful compounds. This could 
in future be followed by in vivo assessments to determine 
the clinical  relevance  of  such  compounds.  This  repre- 





The quest for solutions to the global problem of antibiotic 
resistance in pathogenic bacteria has often focused on 
the isolation and characterization of new antimicrobial 
compounds from a variety of sources including medicinal 
plants. This has seen several medicinal plants being 
screened for antimicrobial activities. Investigations into 
the mechanisms of bacterial resistance have revealed 
that active efflux plays a significant role in the develop-
ment of bacterial acquired and intrinsic resistance. 
Overcoming efflux has therefore been seen as an attract-
tive alternative to circumventing the problem. Bacterial 
efflux pump inhibitors have since been isolated from 
some plants. The combination of such MDR inhibitors 
with antibiotics in vitro has shown that the activities of 
some antibiotics can be dramatically increased even 
against antibiotic resistant strains of bacteria. The large 
varieties of compounds produced by plants have proved 
to have therapeutic potentials as antimicrobials and as 
resistance modifiers. The African biosphere which is 
endowed with the highest plant species biodiversity 
promises to be a potential source of therapeutically useful  
 




compounds, especially from the perspective of their 
potentials in combination with antimicrobial chemothe-
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